Literature DB >> 17401520

Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features.

Ichiro Nakashima1, Toshiyuki Fukazawa, Kohei Ota, Chiyoko Nohara, Yoko Warabi, Takashi Ohashi, Isabelle Miyazawa, Kazuo Fujihara, Yasuto Itoyama.   

Abstract

Seventy-seven cases of the optic-spinal form of multiple sclerosis (OSMS) were collected from 6 institutes in 3 cities of Japan, and the clinical and MRI features were analyzed. Two-thirds of the OSMS patients had longitudinally extensive spinal cord MRI lesions (LESL), and had clinical features similar to those of relapsing neuromyelitis optica which often causes severe disability. In contrast, OSMS patients without LESL tended to have milder disease and had some feature commonly seen in the conventional form of MS. The percentage of OSMS without LESL in total OSMS has recently been increasing. The present study suggests that LESL is crucially important for distinguishing the two subtypes of OSMS.

Entities:  

Mesh:

Year:  2007        PMID: 17401520     DOI: 10.1007/s00415-006-0400-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan.

Authors:  J Kira; K Yamasaki; I Horiuchi; Y Ohyagi; T Taniwaki; Y Kawano
Journal:  J Neurol Sci       Date:  1999-06-15       Impact factor: 3.181

Review 3.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 4.  Multiple sclerosis in the Japanese population.

Authors:  Jun-ichi Kira
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

5.  Neuromyelitis optica: what it is and what it might be.

Authors:  Brian G Weinshenker
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

6.  "OSMS is NMO, but not MS": confirmed by NMO-IgG?

Authors:  Seiji Kikuchi; Toshiyuki Fukazawa
Journal:  Lancet Neurol       Date:  2005-10       Impact factor: 44.182

7.  Decrease in multiple sclerosis with acute transverse myelitis in Japan.

Authors:  I Nakashima; K Fujihara; S Takase; Y Itoyama
Journal:  Tohoku J Exp Med       Date:  1999-05       Impact factor: 1.848

8.  Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity.

Authors:  D Kidd; A J Thompson; B E Kendall; D H Miller; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

9.  Acute transverse myelopathy in multiple sclerosis: clinical and laboratory analyses.

Authors:  T Fukazawa
Journal:  Hokkaido Igaku Zasshi       Date:  1993-01

10.  Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

Authors:  Sean J Pittock; Robyn L McClelland; William T Mayr; Neal W Jorgensen; Brian G Weinshenker; John Noseworthy; Moses Rodriguez
Journal:  Ann Neurol       Date:  2004-08       Impact factor: 10.422

View more
  6 in total

1.  AQP4 antibody-positive Thai cases: clinical features and diagnostic problems.

Authors:  S Siritho; I Nakashima; T Takahashi; K Fujihara; N Prayoonwiwat
Journal:  Neurology       Date:  2011-08-03       Impact factor: 9.910

2.  Spinal cord lesions and disability in Hispanics with multiple sclerosis.

Authors:  L Amezcua; A Lerner; K Ledezma; D Conti; M Law; L Weiner; A Langer-Gould
Journal:  J Neurol       Date:  2013-08-03       Impact factor: 4.849

3.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

4.  Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension.

Authors:  T Kondo; I Kawachi; Y Onizuka; K Hiramatsu; M Hase; J Yun; A Matta; S Torii
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-07-31

5.  Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis.

Authors:  Marcos Papais Alvarenga; Luciana Ferreira do Carmo; Claudia Cristina Ferreira Vasconcelos; Marina Papais Alvarenga; Helcio Alvarenga-Filho; Cleonice Alves de Melo Bento; Carmen Lucia Antão Paiva; Laura Leyva-Fernández; Óscar Fernández; Regina Maria Papais-Alvarenga
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

6.  HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.

Authors:  Mitsuru Watanabe; Yuri Nakamura; Shinya Sato; Masaaki Niino; Hikoaki Fukaura; Masami Tanaka; Hirofumi Ochi; Takashi Kanda; Yukio Takeshita; Takanori Yokota; Yoichiro Nishida; Makoto Matsui; Shigemi Nagayama; Susumu Kusunoki; Katsuichi Miyamoto; Masanori Mizuno; Izumi Kawachi; Etsuji Saji; Takashi Ohashi; Shun Shimohama; Shin Hisahara; Kazutoshi Nishiyama; Takahiro Iizuka; Yuji Nakatsuji; Tatsusada Okuno; Kazuhide Ochi; Akio Suzumura; Ken Yamamoto; Yuji Kawano; Shoji Tsuji; Makoto Hirata; Ryuichi Sakate; Tomonori Kimura; Yuko Shimizu; Akiko Nagaishi; Kazumasa Okada; Fumie Hayashi; Ayako Sakoda; Katsuhisa Masaki; Koji Shinoda; Noriko Isobe; Takuya Matsushita; Jun-Ichi Kira
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.